First Use of Maribavir in Poland to Treat Refractory CMV Disease in a Patient After Kidney Transplantation.

 0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Monika Knysak, Norbert Kwella, Anna Pawłowska, Tomasz Stompór, Justyna Zbrzeźniak-Suszczewicz

Ngôn ngữ: eng

Ký hiệu phân loại: 297.1248 Sources of Islam

Thông tin xuất bản: United States : Transplantation proceedings , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 702861

Cytomegalovirus (CMV) is one of the most common opportunistic infections affecting solid organ transplant recipients (SOTRs). In this article, we presented the case of a 39-year-old patient with end-stage renal disease after kidney transplantation with refractory CMV infection, who was successfully treated with maribavir for the first time in Poland. The use of maribavir resulted in a significant reduction of CMV viremia in ganciclovir/valganciclovir-resistant CMV infection and resolution of CMV disease symptoms in the absence of drug-related adverse events.
Tạo bộ sưu tập với mã QR

THƯ VIỆN - TRƯỜNG ĐẠI HỌC CÔNG NGHỆ TP.HCM

ĐT: (028) 36225755 | Email: tt.thuvien@hutech.edu.vn

Copyright @2024 THƯ VIỆN HUTECH